Skip to content
2000
Volume 9, Issue 5
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

Alzheimer's disease is a chronic and progressive neurodegenerative disorder. The presence of functional cannabinoid CB2 receptors in central nervous system (CNS) has provoked that this receptor and its agonist ligands are now considered as promising pharmacological targets for neurological diseases. Herein, we review the evidences supporting the potential role of the ECS as a therapeutic target, focused on CB2 receptor and its ligands, for the treatment of Alzheimer 's disease.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/138955709788167628
2009-05-01
2025-10-02
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/138955709788167628
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test